The discovery of recombinant DNA proved that biology, not chemistry alone, could create new medicines like life-saving insulin.

Story May 12 - NGM Bio: The biotech is shedding around 75% of staff, pausing development of a phase 2 liver disease asset and halting further investment in discovery and preclinical work.

PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the ...

Genentech, a member of the Roche Group, will create 400 jobs with a new biotechnology facility in Holly Springs, Wake County, ...

Find out the best way to find the right CDMO for your biotech. Experts shared some advice to help companies through the ...

The FDA did not respond to a request for comment. U.S. Health Secretary Robert F. Kennedy Jr. has said that the agency's ...

Successful research and development in health biotechnology is taking place in several countries that typically are classified as lower income countries or developing countries. With a view to ...

Enliven Therapeutics has decided against taking its phase 1-stage solid tumor drug into further development next year in ...

With long development timelines and high burn rates, biotech companies must navigate capital markets with precision.

Q1 2025 Earnings Call Transcript May 14, 2025 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is ...

Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), today announced the ...